Hormone-based drugs may help in reducing weight
According to the study, an obese person would cycle between different drug therapies over the course of a month to achieve a greater degree of body weight loss compared to the effects achieved with either a single drug or the continuous combination of drugs.
![Combination of hormone-based drugs can produce enhanced weight loss (File Photo)](https://www.dynamitenews.com/images/2017/07/19/hormone-based-drugs-may-help-in-reducing-weight/596f088546630.jpeg)
Washington D.C: A team of researchers has recently revealed that a unique combination of hormone-based drugs can produce enhanced weight loss.
Senior author Dr. Matthew Hayes from the University of Pennsylvania in the US said that imagine a drug regimen, where an obese person would cycle between different drug therapies over the course of a month to achieve a greater degree of body weight loss compared to the effects achieved with either a single drug or the continuous combination of drugs.
Also Read: Do you know why men gain weight after marriage?
His team studied the combination of two different drug classes that target different hormones: amylin and glucagon-like peptide-1 (GLP-1).
They found that the combined treatments acted synergistically to suppress feeding and body weight.
They also discovered that the weight-loss effects of chronic amylin- and GLP-1-based combination therapies could be enhanced, when obese lab animals are cycled through their drug treatments.
Lead author Kieran Koch-Laskowski said that the idea of drug-cycling is nothing new.
Also Read: Childhood obesity can later risk kids' arteries
Koch-Laskowski stated that millions of women on birth control pills, for example, already take daily pills that cycle between drug and placebo throughout the month.
![](http://www.dynamitenews.com/images/2017/07/19/hormone-based-drugs-may-help-in-reducing-weight/41a1763.jpg)
The research has found that these enhanced weight-loss effects with a combination of drugs that are either already FDA approved or in clinical trials for metabolic diseases.
The research is scheduled to be presented at the Annual Meeting of the Society.(ANI)